Expression of proliferation and apoptosis-related proteins in usual ductal hyperplasia of the breast

Human Pathology

Volumn 29, Issue 12, 1998, Pages 1539-1545

  Mommers, Ellen C M ^a   Van Diest, Paul J ^a   Leonhart, Angelique M ^a   Meijer, Chris J L M ^a   Baak, Jan P A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Apoptosis; Breast; Hyperplasia; Immunohistochemistry; Proliferation

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53;

APOPTOSIS; ARTICLE; BREAST CARCINOGENESIS; BREAST DUCT; BREAST HYPERPLASIA; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; PROTEIN EXPRESSION;

EID: 0031646983     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(98)90028-4     Document Type: Article

References (33)

1. Page DL, Anderson TJ, Rogers LW: Epithelial hyperplasia, in Page DL, Anderson TJ (eds): Diagnostic Histopathology of the Breast. Edinburgh, Scotland, Churchill Livingstone, 1987, pp 120-156
2. Carter CL, Corle DK, Micozzi MS, et al: A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiol 128:467-477, 1988
3. Pavelic ZP, Pavelic L, Lower EE, et al: c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. Cancer Res 52:2597-2602, 1992
4. De Potter CR, Schelfhout A-M: The neu-protein and breast cancer. Virchows Arch 426:107-115, 1995
5. Silvestrini R, Veneroni S, Daidone MG, et al: The bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86:499-504, 1994
6. Joensuu H, Pylkkänen L, Toikkanen S: Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 145:1191-1198, 1994
7. Visscher DW, Sarkar F, Tabaczka P, et al: Clinicopathologic analysis of bcl-2 immunostaining in breast carcinoma. Mod Pathol 9:642-646, 1996
8. waf1 immunohistochemical expression in breast carcinoma: Correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br J Cancer 74:208-215, 1996
9. kip1 protein: Prognostic implications in primary breast cancer. Nature Med 3:227-230, 1997
10. Borg A, Sigurdsson H, Clark GM, et al: Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. Br J Cancer 63:136-142, 1991
11. Schuuring E, Verhoeven E, Van Tinteren H, et al: Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res 52:5229-5234, 1992
12. Van Diest PJ, Michalides RJAM, Jannink I, et al: Cyclin D1 expression in invasive breast cancer: Correlations and prognostic value. Am J Pathol 150:705-711, 1997
13. Michalides R, Hageman P, Van Tinteren H, et al: A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 73:728-734, 1996
14. McIntosh GG, Anderson JJ, Milton I, et al: Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 11:885-891, 1995
15. Leal CB, Schmitt FC, Bento MJ, et al: Ductal carcinoma in situ of the breast: Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein. Cancer 75:2123-2131, 1995
16. Schmitt FC, Figueiredo P, Lacerda M: Expression of c-erbB-2 protein and DNA ploidy in breast carcinogenesis. Arch Pathol Lab Med 119:815-820, 1995
17. Schmitt FC, Leal C, Lopes C: p53 protein expression and nuclear DNA content in breast intraductal proliferations. J Pathol 176:233-241, 1995
18. Siziopikou KP, Prioleau JE, Harris JR, et al: Bcl-2 expression in the spectrum of preinvasive breast lesions. Cancer 77:499-506, 1996
19. Weinstat-Saslow D, Merino MJ, Manrow RE, et al: Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nature Med 1:1257-1260, 1995
20. Allred DC, Clark GM, Molina R, et al: Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. HUM PATHOL 23:974-979, 1992
21. Umekita Y, Takasaki T, Yoshida H: Expression of p53 protein in benign epithelial hyperplasia, atypical ductal hyperplasia, noninvasive and invasive mammary carcinoma: An immunohistochemical study. Virchows Arch 424:491-494, 1994
22. Alle KM, Henshall SM, Field AS, et al: Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin Cancer Res 4:847-854, 1998
23. Jacobs TW, Prioleau JE, Stillman IE, et al: Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 88:1054-1059, 1996
24. Bobrow MN, Litt GJ, Shaughnessy KJ, et al: The use of catalyzed reporter deposition as a means of signal amplification in a variety of formats. J Immunol Methods 150:145-149, 1992
25. Anderson TJ, Battersby S, King RJB, et al: Oral contraceptive use influences resting breast proliferation. HUM PATHOL 20:1139-1144, 1989
26. Schmitt FC, Figueiredo P, Lacerda M: Expression of c-erbB-2 protein and DNA ploidy in breast carcinogenesis. Arch Pathol Lab Med 119:815-820, 1995
27. Lodato R, Maguire H, Greene M, et al: Immunohistochemical evaluation of c-erb-B-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod Pathol 3:449-454, 1990
28. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149-1163, 1995
29. Hamel PA, Hanley-Hyde J: G1 cyclins and control of the cell division cycle in normal and transformed cells. Cancer Invest 15:143-152, 1997
30. Slingerland JM, Hengst L, Pan C-H, et al: A novel inhibitor of cyclin-cdk activity detected in transforming growth factor β-arrested epithelial cells. Mol Cell Biol 14:3683-3694, 1994
31. kip1, a cyclin-cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 8:9-22, 1994
32. Anderson TI, Holm R, Nesland JM, et al: Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 68:540-548, 1993
33. Thor AD, Moore DH, Edgerton SM, et al: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992